欧林生物: 成都欧林生物科技股份有限公司股票交易异常波动公告

Core Viewpoint - The stock of Chengdu Olin Biological Technology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 18 to August 20, 2025, prompting the company to conduct a self-examination and confirm the normality of its business operations [1][3][4]. Group 1: Business Operations - The company confirmed that its daily operations are normal, with no significant changes or fluctuations in production costs and sales [1][2][3]. - The company is actively progressing in product research, production, and sales, with no major adjustments in the market environment or industry policies [1][2]. Group 2: Major Events - As of the announcement date, the company reported no undisclosed significant information or ongoing major asset restructuring, share issuance, or other substantial events [2][3]. - The company has not identified any media reports or market rumors that could significantly impact its stock price [2][3]. Group 3: Stock Performance - The closing price of the company's stock on August 20, 2025, was 33.11 yuan per share, with a significant price increase compared to most peers in the industry and the Shanghai Composite Index [3][5]. - The company's rolling price-to-earnings (P/E) ratio is 338.72, which is significantly higher than the industry average P/E ratio of 32.11, indicating a potential short-term market overheating risk [3][5].